



Company Announcement

Amendment to Appendix 4E

Thursday, Australia August 30th 2007

Please note a typographical error has occurred in the Appendix 4E issued 29th August 2007. On page 4, section 4, Outlook, should read "The trial in EPP is on track to be concluded by March 2009, the trial in PLE by March 2009".

This is consistent with Clinuvel communications over the past 12 months.

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited (ASX:**CUV**, XETRA/DAX:**UR9**, ADR:**CLVLY**) is an Australian biopharmaceutical company developing its photo-protective drug CUV1647 as a preventative treatment for a range of UV-related skin disorders as well as in cancer related treatments.

The five indications are:

Indication	Description	Clinical Trial Status
Polymorphic Light Eruption (PLE / PMLE)	Sun poisoning	Phase III trials began May 2007
Erythropoietic Protoporphyrria (EPP)	Absolute sun intolerance	Phase III trials began June 2007
Squamous Cell Carcinoma (SCC) and Actinic Keratosis (AK) in organ transplant patients	Non-melanoma skin cancers / precursor to skin cancers	Phase II trials planned to begin 2007
Solar Urticaria (SU)	Acute anaphylactic reaction to sun	Phase II trials planned to begin 2007
Phototoxicity associated with Photodynamic Therapy (PDT)	Photo-sensitivity associated with cancer treatment	Phase II trials planned to begin 2007

Phase I and II human clinical trials using CUV1647 have demonstrated that the drug is well tolerated and no significant safety concerns have been identified to date.

Following successful conclusion of the development program, Clinuvel will work closely with global regulators to facilitate marketing approval of CUV1647.

-END-

For more information contact:

Colin Mackie
Head of Corporate Development
Clinuvel Pharmaceuticals Limited
Tel: +61 3 9660 4900
investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its leading drug candidate, CUV1647, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for CUV1647 can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for CUV1647 is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

**Level 11 / 330 Collins Street T +61 3 9660 4900 www.clinuvel.com
Melbourne, Victoria 3000 F +61 3 9660 4999
Australia**